More than 4,000 patients: what the hPG80 studies show
26 clinical studies, 4,045 patient samples and 1,199 samples from healthy volunteers.¹
Where the figure of 4,000 patients comes from
The pooled data come from 26 case-control clinical studies: 22 retrospective and four prospective. These studies compare people with cancer with healthy people.¹

They include nearly 1,200 healthy volunteers with no symptoms, representing 1,199 samples, and more than 4,000 patients with 16 types of cancer, representing 4,045 samples.¹
The median hPG80 level is 1.5 pmol/L in healthy people, compared with 4.6 pmol/L in patients with cancer, across all stages.¹
Median hPG80 level by cancer stage
pmol/L
| Cancer | Patients |
|---|---|
| Lung | 829 |
| Breast | 712 |
| Prostate | 608 |
| Colorectal | 373 |
| Gynaecological | 302 |
| Liver | 300 |
| Kidney | 232 |
| Oesophagus/stomach | 137 |
| Skin melanoma | 133 |
| Neuroendocrine | 129 |
| Pancreas | 108 |
| Brain | 102 |
| Head and neck | 49 |
| Eye melanoma | 31 |
The foundational study (EBioMedicine, 2020)
The foundational study compares 1,546 patients with 11 types of cancer with 557 healthy blood donors. The cancers studied are breast, uterine, ovarian, prostate, kidney, colorectal, pancreatic, oesophageal/stomach and liver cancer, cutaneous melanoma and lung cancer.²

The median hPG80 level is 4.88 pmol/L in patients, compared with 1.05 pmol/L in donors. Depending on the cancer type, it ranges from 2.50 pmol/L for breast cancer to 11.65 pmol/L for liver cancer.²
Monitoring during treatment shows a decrease in levels after surgery in most patients. A decrease of more than 25% is observed in 74% of the patients followed.²
In liver cancer, the median level is 1.99 pmol/L during remission, compared with 15.71 pmol/L when the disease is active. These findings describe how the marker changes during treatment and disease follow-up.²
The prospective ONCOPRO study (Biomarker Research, 2025)
The prospective ONCOPRO study, conducted at Hospices Civils de Lyon and registered under NCT03787056, enrolled 506 patients between 2018 and 2022.³
Of these, 421 patients across 16 cancer types could be included in the analysis. They were compared with 330 healthy people.³
The median hPG80 level is 3.8 pmol/L in patients, compared with 1.9 pmol/L in healthy people. This large prospective study confirms substantially higher levels in patients with cancer.³
Prevonco is currently available in France only.
An aid to the early detection of 16 cancers
No prescription needed, for people without symptoms. If you have an unexplained symptom, see your doctor first.
Pre-register for free →Sources
- 1.biodena.care
- 2.You et al., « The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients », EBioMedicine, 2020 ; 51 : 102574
- 3.You et al., « Diagnostic value of the wnt target and cancer-associated blood biomarker hPG80: ONCOPRO case-control prospective study », Biomarker Research, 2025 — NCT03787056